Poseida Therapeutics, Inc.
NASDAQ:PSTX
3.07 (USD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Poseida Therapeutics, Inc. |
Symbool | PSTX |
Munteenheid | USD |
Prijs | 3.07 |
Beurswaarde | 298,201,073 |
Dividendpercentage | 0% |
52-weken bereik | 1.83 - 4.27 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Mark J. Gergen J.D. |
Website | https://www.poseida.com |
An error occurred while fetching data.
Over Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)